Serum-free Media Market Global Size, Share, Future Challenges, Revenue, Demand, Industry Growth and Top Players Analysis to 2022-2030

Protein-free Medium Gauges Demand to Overcome Challenges in COVID-19 Vaccine Production

With many around the world affected by the COVID-19, pharmaceutical companies are boosting their production capabilities to develop vaccines. Such trends are creating revenue opportunities for players in the serum-free media market. Lonza Group – a Swiss multinational chemicals and biotechnology company, is gaining recognition for its ProVeroTM1 Serum-free Medium, which is of non-animal origin and supports vaccine production.

Companies in the serum-free media market are taking cues from such innovations and increasing the availability of protein-free medium, which is optimized for fast cell proliferation. They are developing several serum-free media (SFM) options that help to reduce production variables for vaccine production. In order to avoid any challenges during the downstream processing of recombinant protein or vaccine production, manufacturers are opting for protein-free medium.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111494

Low Levels of Human Recombinant Insulin in Media Facilitates Downstream Processing

The global serum-free media market is projected to reach US$ 660.4 Mn by 2031. Manufacturers are increasing their output capacities in customized cell culture media. Thermo Fisher Scientific – the U.S. provisioner of scientific instrumentation, reagents & consumables, and software services, is publicizing its Gibco serum-free media, which promotes superior cell growth and viability.

Manufacturers in the serum-free media market are developing medium that enable precise evaluations of cellular function and facilitate consistent performance. Enhanced detection of cellular mediators and for better control over physiological responsiveness is preferred in serum-free media. The absence of proteins and only very low levels of human recombinant insulin facilitate both downstream processing and regulatory compliance.

Key Components of SFM Optimized to Develop Recombinant Therapeutic Proteins

The increasing demand for recombinant protein products is fueling the production of serum-free media. The serum-free media market is expected to advance at a favorable CAGR of 7% during the forecast tenure. Different media contain different formulations that have the potential to adapt to the growth of different cell lines and the production of recombinant protein.

Based on the characteristics of Chinese hamster ovary (CHO) cells and its advantages in recombinant therapeutic protein (RTP) production, key components of SFM are being optimized to different degrees and proportions. The Plackett Burman method (PBM) and the response surface method are routinely used for SFM optimization and can be combined with other statistical methods such as non-parametric Gaussian kernel regression.

View full report@ https://qyresearchmedical.com/report/serum-free-media-market-media-type-cho-cell-media-protein-expression-media-immunology-media-insect-cell-media-hybridoma-media-stem-cell-media-and-chemically-defined-media-and-end-user-biopharma-industry-c-2021-2031/111494

FBS-free Medium Eliminates Possibility of Lot Variations in MSCs During Manufacture

Mesenchymal Stem/Stromal Cells (MSCs) hold promising potentials for treating a variety of conditions in veterinary medicine. MSCs are isolated and expanded invitro in a medium that is supplemented with fetal bovine serum (FBS). However, the use of FBS as a medium component during manufacturing may pose several issues. Since FBS can be a source of unwanted pathogens, companies in the serum-free media market are partnering with researchers to develop FBS-free medium that supports both isolation and expansion of MSCs from canine adipose tissue, while removing unwanted pathogens, immune response, and lot-to-lot variations.

Serum-free Hybridoma Helps Prevent Contamination of Cell Culture Facilities

Companies in the serum-free media market are boosting the production of hybridoma media. Leinco Technologies – a biotechnology company in Fenton, Missouri, is gaining popularity for its AlphaGrow Serum Free Hybridoma that offers better lot-to-lot consistency in applications. Increased antibody production and low cost attributes of serum-free hybridoma are being preferred by researchers and scientists.

The inconveniences of serum include the need to screen lots and is subject to variability in cost & quality. Companies are capitalizing on this opportunity, since the presence of contaminating bovine IgG creates issues for researchers. Such findings are triggering the demand for serum-free hybridoma media, as animal-derived ingredients carry the risk of introducing adventitious agents such as viruses and prions that can contaminate cell culture facilities.

Serum-free Cell Culturing Gaining Prominence in Biological Facilities

Apart from CHO cell media and protein expression media, companies in the serum-free media market are increasing their focus on human microglial cell culture serum-free media. On the other hand, serum-free cell culturing is gaining recognition in biological facilities. Researchers in cell biology are familiar with adding bovine or calf serum to cell cultures. Unfortunately, adding serum means adding a highly variable and non-standardized product to a well ordered system. Hence, manufacturers are leveraging this opportunity to boost product innovations.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111494/2900

Companies are increasing the availability of chemically defined serum-free media. Serum-free cell culturing is gaining market prominence, since objections have been raised to the use of serum in cell culture on regulatory and ethical grounds.

Analysts’ Viewpoint

Media formulations without FBS are essential for COVID-19 vaccine production and has led to the popularity of protein-free medium. Since FBS is associated with inconsistencies between batches of MSCs, companies in the serum-free media market should develop FBS-free medium that supports both isolation and expansion of MSCs from canine adipose tissue, while removing unwanted pathogens, immune response, and lot-to-lot variations.

Serum-free hybridoma media ensures consistent downstream purification results. This medium eliminates ethical concerns surrounding the collection of FBS. MSCs cultivated in FBS-free media exhibits a more uniform size and shorter population doubling time as compared to the FBS medium. Manufacturers are boosting credibility credentials by minimizing waste in labs by adopting bottles that utilize less source material than comparable media bottles on the market.

Serum-free Media Market: Overview

According to Transparency Market Research’s latest research report on the global serum-free media market for the historical period 2017–2019 and the forecast period 2021–2031, easier downstream processing of products after production from media and increase in demand for various recombinant proteins & types of culture are projected to drive the global serum-free media market during the forecast period

According to the report, the global serum-free media market was valued at US$ 320 Mn in 2020 and is anticipated to expand at a CAGR of 7% from 2021 to 2031

Easier Downstream Processing of Products Post Production from Media

Concentration of proteins in serum media is generally higher than proteins produced by mammalian cells in vivo, which makes separation of target molecule difficult

Serum proteins in cell culture media are significant contaminants and could interact with the component of interest, resulting in slow purification of the molecule

The inVitro protein concentration is low in serum-free media, resulting in low levels of contaminants. Hence, the target protein (lead molecule) is easier to purify with higher recovery through various methods such as centrifugation, HPLC, and mass spectrometry.

Once the protein is produced in the serum-free media, it is tested for accuracy through various methods such as SDS PAGE, and mass spectrometry, which gives an idea whether the isolated protein is of interest

Therefore, easier downstream processing of products post production from media is a major driver for the global serum-free media market

Increase in Demand for Various Recombinant Proteins and Types of Culture

Presently, demand for pain relief devices is high due to arthritic pain, joint pain, knee pain, etc. Additionally, increase in incidence and prevalence of arthritis & joint diseases drive the demand of pain relief devices.

According to CDC, one in every 30 adults in the U.S. suffers from pain problems, which is considered the eighth leading risk factor for disability and premature deaths. Medication and lifestyle changes are effective and affordable; however, the overall rate of pain relief control is suboptimal.

Serum-free media is used in various types of suspension & adherent cultures for the production of immunological cells such as IL-2, IL-4, cytotoxic lymphocytes (CTLs), and monocytes, which are used in production of various vaccines

Hence, increase in demand for recombinant proteins in various chronic diseases such as cancer is likely to propel the global serum-free media market

Continuous Research & Development for Development of Novel Therapeutic Drugs

Need of development of novel therapeutic drugs has increased due to various disadvantages associated with conventional and regular drugs due to their associated side effects and ineffectiveness in providing the required relief from the particular body indication

Various research organizations and healthcare companies are involved in finding a better and modified version of existing drugs that not only can provide relief to various disease indications, but can also treat major diseases such as cancer

Healthcare pharmaceutical & drug manufacturing companies are making significant investment in the research & development of novel therapeutic drugs, owing to increase in patient care and preference for these drugs

Serum-free media is gaining popularity among major industry players. Hence, the serum-free media market is anticipated to expand at a high CAGR during the forecast period.

Serum-free Media Market: Competition Landscape

This report profiles major players operating in the global serum-free media market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global serum-free media market is moderately fragmented with the presence of a large number of leading players and several small players in regional markets. Top players account for major share of the global serum-free media market.

Prominent players operating in the global serum-free media market include

  • Thermo Fisher Scientific
  • Athena Environmental Sciences
  • Pan Biotech
  • Bichrom
  • Irvine Scientific
  • Biological Industries
  • Sigma-Aldrich
  • CellGenix
  • HiMedia Laboratories

The report on the global serum-free media market discusses individual strategies, followed by company profiles. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global serum-free media market.

Key Questions Answered in Global Serum-free Media Market Report

  • What is the sales/revenue generated by the serum-free media market across all regions during the forecast period?
  • What are the opportunities in the global serum-free media market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which product segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Serum-free Media Market – Segmentation

Media Type

  • CHO Cell Media
  • Protein Expression Media
  • Immunology Media
  • Insect Cell Media
  • Hybridoma Media
  • Stem Cell Media
  • Chemically Defined Media

End-user

  • Biopharma Industry
  • Clinical Research Organizations
  • Research Centers
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Serum-free Media Market

4. Market Overview

4.1. Introduction

4.1.1. Media type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Serum-free Media Market Analysis and Forecast, 2018–2030

4.4.1. Market Revenue Projections (US$ Mn)

4.4.2. Market Volume/Unit Shipments Projections

5. Key Insights

5.1. Key Product/brand Analysis

5.2. Applications of different Serum-free Media’s in Cell culture

5.3. COVID-19 Pandemic Impact on Serum-free Media Market

6. Global Serum-free Media Market Analysis and Forecast, by Media Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Media Type, 2017-2031

6.3.1. CHO Cell Media

6.3.2. Protein Expression Media

6.3.3. Immunology Media

6.3.4. Insect Cell Media

6.3.5. Hybridoma Media

6.3.6. Stem Cell Media

6.3.7. Chemically-defined Media

6.4. Market Attractiveness Analysis, by Media Type

7. Global Serum-free Media Market Analysis and Forecasts, By End-user

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by End-user, 2017–2031

7.3.1. Biopharma Industry

7.3.2. Clinical Research Organizations

7.3.3. Research Centers

7.3.4. Others

7.4. Market Attractiveness Analysis, by End-user

8. Global Serum-free Media Market Analysis and Forecasts, By Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness Analysis, by Region

9. North America Serum-free Media Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast, by Media Type, 2017–2031

9.2.1. CHO Cell Media

9.2.2. Protein Expression Media

9.2.3. Immunology Media

9.2.4. Insect Cell Media

9.2.5. Hybridoma Media

9.2.6. Stem Cell Media

9.2.7. Chemically-defined Media

9.3. Market Value Forecast, by End-user, 2017–2031

9.3.1. Biopharma Industry

9.3.2. Clinical Research Organizations

9.3.3. Research Centers

9.3.4. Others

9.4. Market Value Forecast, by Country, 2017–2031

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Media Type

9.5.2. By End-user

9.5.3. By Country

10. Europe Serum-free Media Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Media Type, 2017–2031

10.2.1. CHO Cell Media

10.2.2. Protein Expression Media

10.2.3. Immunology Media

10.2.4. Insect Cell Media

10.2.5. Hybridoma Media

10.2.6. Stem Cell Media

10.2.7. Chemically-defined Media

10.3. Market Value Forecast, by End-user, 2017–2031

10.3.1. Biopharma Industry

10.3.2. Clinical Research Organizations

10.3.3. Research Centers

10.3.4. Others

10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis

10.5.1. By Media Type

10.5.2. By End-user

10.5.3. By Country/Sub-region

11. Asia Pacific Serum-free Media Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Media Type, 2017–2031

11.2.1. CHO Cell Media

11.2.2. Protein Expression Media

11.2.3. Immunology Media

11.2.4. Insect Cell Media

11.2.5. Hybridoma Media

11.2.6. Stem Cell Media

11.2.7. Chemically-defined Media

11.3. Market Value Forecast, by End-user, 2017–2031

11.3.1. Biopharma Industry

11.3.2. Clinical Research Organizations

11.3.3. Research Centers

11.3.4. Others

11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis

11.5.1. By Media Type

11.5.2. By End-user

11.5.3. By Country/Sub-region

12. Latin America Serum-free Media Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Media Type, 2017–2031

12.2.1. CHO Cell Media

12.2.2. Protein Expression Media

12.2.3. Immunology Media

12.2.4. Insect Cell Media

12.2.5. Hybridoma Media

12.2.6. Stem Cell Media

12.2.7. Chemically-defined Media

12.3. Market Value Forecast, by End-user, 2017–2031

12.3.1. Biopharma Industry

12.3.2. Clinical Research Organizations

12.3.3. Research Centers

12.3.4. Others

12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis

12.5.1. By Media Type

12.5.2. By End-user

12.5.3. By Country/Sub-region

13. Middle East & Africa Serum-free Media Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Media Type, 2017–2031

13.2.1. CHO Cell Media

13.2.2. Protein Expression Media

13.2.3. Immunology Media

13.2.4. Insect Cell Media

13.2.5. Hybridoma Media

13.2.6. Stem Cell Media

13.2.7. Chemically-defined Media

13.3. Market Value Forecast, by End-user, 2017–2031

13.3.1. Biopharma Industry

13.3.2. Clinical Research Organizations

13.3.3. Research Centers

13.3.4. Others

13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis

13.5.1. By Media Type

13.5.2. By End-user

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share Analysis by Company (2020)

14.3. Company Profiles

14.3.1. Thermo Fisher Scientific

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Product Portfolio

14.3.1.3. SWOT Analysis

14.3.1.4. Strategic Overview

14.3.2. Athena Environmental Sciences

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Product Portfolio

14.3.2.3. SWOT Analysis

14.3.2.4. Strategic Overview

14.3.3. Pan Biotech

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Product Portfolio

14.3.3.3. SWOT Analysis

14.3.3.4. Strategic Overview

14.3.4. Sigma-Aldrich

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Product Portfolio

14.3.4.3. SWOT Analysis

14.3.4.4. Strategic Overview

14.3.5. CellGenix

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Product Portfolio

14.3.5.3. SWOT Analysis

14.3.5.4. Strategic Overview

14.3.6. HiMedia Laboratories

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Product Portfolio

14.3.6.3. SWOT Analysis

14.3.6.4. Strategic Overview

14.3.7. Biological Industries

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Product Portfolio

14.3.7.3. SWOT Analysis

14.3.7.4. Strategic Overview

14.3.8. Irvine Scientific

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Product Portfolio

14.3.8.3. SWOT Analysis

14.3.8.4. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111494/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi